Michael J. Stocks
Impact in
- Physiology top 2%
- Adenosine and Purinergic Signaling
- Molecular Medicine top 5%
- Antibiotic Resistance in Bacteria
Papers in
-
- Adenosine and Purinergic Signaling 7
- Co-authors
- Lilian AlcarazMiguel CámaraFadi SoukariehPaul WilliamsMark FurberBarrie KellamDavid R. CheshireDavid J. Liptrot
- Journals
- Journal of Medicinal Chemistry (11 papers)Bioorganic & Medicinal Chemistry Letters (10 papers)ACS Medicinal Chemistry Letters (7 papers)Synlett (6 papers)Tetrahedron Letters (6 papers)
- Partner nations
- United KingdomSwedenTaiwan
In The Last Decade
Michael J. Stocks
78 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 98
- Physiology 155
- Molecular Medicine 142
- Organic Chemistry 698
- Pharmaceutical Science 72
- Molecular Biology 800
Countries citing papers authored by Michael J. Stocks
This map shows the geographic impact of Michael J. Stocks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Stocks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Stocks more than expected).
Fields of papers citing papers by Michael J. Stocks
This network shows the impact of papers produced by Michael J. Stocks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Stocks. The network helps show where Michael J. Stocks may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael J. Stocks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 10 | |
| 3 | 2024 | 0 | |
| 4 | 2024 | 6 | |
| 5 | 2024 | 5 | |
| 6 | 2023 | 3 | |
| 7 | 2023 | 2 | |
| 8 | 2023 | 7 | |
| 9 | 2023 | 5 | |
| 10 | 2022 | 4 | |
| 11 | 2022 | 11 | |
| 12 | 2022 | 13 | |
| 13 | 2021 | 28 | |
| 14 | 2020 | 6 | |
| 15 | 2019 | 3 | |
| 16 | 2018 | 46 | |
| 17 | 2018 | 121 | |
| 18 | 2018 | 2 | |
| 19 | 2017 | 8 | |
| 20 | 2017 | 14 |
About Michael J. Stocks
Michael J. Stocks is a scholar working on Physiology, Molecular Medicine, Organic Chemistry, Molecular Biology and Virology, having authored 81 papers that have together received 1.6k indexed citations. Recurring topics across this work include Receptor Mechanisms and Signaling (9 papers), Signaling Pathways in Disease (8 papers), Peptidase Inhibition and Analysis (7 papers), Adenosine and Purinergic Signaling (7 papers), Bacterial biofilms and quorum sensing (6 papers), Chemical Synthesis and Analysis (6 papers), Synthetic Organic Chemistry Methods (6 papers) and Inhalation and Respiratory Drug Delivery (6 papers). The work is most often cited by research in Physiology (155 citations), Molecular Medicine (142 citations), Organic Chemistry (698 citations), Pharmaceutical Science (72 citations) and Molecular Biology (800 citations). Michael J. Stocks has collaborated with scholars based in United Kingdom, Sweden and Taiwan. Frequent co-authors include Lilian Alcaraz, Miguel Cámara, Fadi Soukarieh, Paul Williams, Mark Furber, Barrie Kellam, David R. Cheshire, David J. Liptrot, Tim Luker and Bryan Roberts. Their work appears in journals such as Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, ACS Medicinal Chemistry Letters, Synlett and Tetrahedron Letters.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.